Evidence map›Paper›PMID 40553277›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

O

Petar Miletic, Benjamin Brakel, Chitra Venugopal, Sheila K Singh

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Petar MileticMcMaster Centre for Discovery and Cancer Research, McMaster University, Hamilton, ON, Canada.
Benjamin BrakelMcMaster Centre for Discovery and Cancer Research, McMaster University, Hamilton, ON, Canada.
Chitra VenugopalMcMaster Centre for Discovery and Cancer Research, McMaster University, Hamilton, ON, Canada.
Sheila K SinghMcMaster Centre for Discovery and Cancer Research, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The alkylating agent temozolomide is used to treat patients who have glioblastoma. However, treatment is only effective when O6-methylguanine-DNA methyltransferase is silenced in the cancer cells. The best way to assess whether or not a patient will be responsive to treatment is to determine if the promoter region of the O6-methylguanine-DNA methyltransferase gene is methylated. Similarly, knowing the methylation status of the O6-methylguanine-DNA methyltransferase promoter in patient -derived brain tumor initiating cells can help guide research. Here we describe how to determine the methylation status in vitro using bisulfite conversion followed by methylation-specific PCR.

Indexed as

Brain NeoplasmsDNA MethylationDNA Modification MethylasesDNA Repair EnzymesGlioblastomaO(6)-Methylguanine-DNA MethyltransferasePromoter Regions, GeneticTumor Suppressor ProteinsHumansPolymerase Chain ReactionSulfitesTemozolomideDNA Modification MethylasesDNA Repair Enzymeshydrogen sulfiteMGMT protein, humanO(6)-Methylguanine-DNA MethyltransferaseSulfitesTemozolomideTumor Suppressor ProteinsBisulfite ConversionGlioblastomaMethylationO6-Methylguanine–DNA Methyltransferase (MGMT)

Identifiers

PMID40553277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.